Body Dysmorphic Disorder and Cosmetic Injectables: What the Evidence — and Australia's Leading Experts

The question the industry avoided for too long

For years, the Australian cosmetic injectables sector operated with a structural blind spot. A patient could book online, sit down with an injector they'd never met, point at a filtered selfie, and walk out forty minutes later with prescription-only medicines in their face. The people most likely to be harmed by that process — patients with underlying body dysmorphic disorder (BDD) — were also the people most likely to be repeat customers. That was a commercial feature, not a bug. It took regulatory intervention, not self-regulation, to start closing the gap.

As of 2 September 2025, the Australian Health Practitioner Regulation Agency's (AHPRA) Guidelines for Registered Health Practitioners Who Perform Non-Surgical Cosmetic Procedures require every practitioner performing cosmetic injectables, fat-dissolving injections, thread lifts, laser treatments and similar procedures to undertake an evidence-based psychological assessment — including screening for BDD — before treatment. This follows the Medical Board of Australia's 2023 guidelines for surgical cosmetic procedures, which introduced equivalent requirements for plastic and cosmetic surgeons.¹ ²

This article explains what BDD is, why it matters more in cosmetic medicine than almost any other setting, what the evidence says about outcomes, and where Australian patients and practitioners can turn for help from the country's leading researchers and clinicians.

What BDD actually is — and isn't

Body dysmorphic disorder is a recognised psychiatric diagnosis in the DSM-5-TR. It is characterised by preoccupation with one or more perceived defects or flaws in physical appearance that are either not observable or appear slight to others, accompanied by repetitive behaviours (mirror checking, excessive grooming, skin picking, reassurance seeking) or mental acts (comparing one's appearance with others'). The preoccupation causes clinically significant distress or impairment in social, occupational or other important areas of functioning.

BDD is not vanity. It is not perfectionism. It is not "being particular" about how you look. It is an often-debilitating illness with substantial comorbidity — including depression, social anxiety disorder, obsessive-compulsive disorder, eating disorders, and — critically — elevated rates of suicidal ideation and attempts.

Professor Susan Rossell of Swinburne University's Centre for Mental Health, one of the most cited BDD researchers in the world, has spent two decades demonstrating that BDD is a distinct disorder with its own neurocognitive signature — not simply a subtype of OCD, as it was long assumed. Her neuroimaging work shows measurable differences in visual processing and frontal brain regions in people with BDD, which helps explain why sufferers genuinely do not see themselves the way others see them.³

That last point is the single most important thing for cosmetic patients to understand. BDD is, among other things, a perceptual disorder. The mirror is not reliable. Which means a procedure that "fixes" what the patient sees will, more often than not, fail to fix what the patient feels.

The Australian data: why cosmetic medicine is a front-line setting

BDD affects roughly 2% of the general population globally, with rates as high as 4.4% among young adults and adolescents.³ Those figures rise sharply in cosmetic settings.

In 2021, Dr Toni Pikoos and colleagues published what remains the most cited Australian study on the subject — "Is the needle as risky as the knife?" — which examined BDD prevalence in women presenting for minor (non-surgical) cosmetic procedures. The study found that rates of probable BDD among women seeking injectables were substantially higher than in the general population, and that these patients reported lower satisfaction and higher distress after treatment.⁴ The title matters: it explicitly challenges the long-held industry assumption that because injectables are "minor," the psychological stakes are also minor. The data says otherwise.

A subsequent paper by Rossell, Castle, Pikoos and Malcolm — bluntly titled "Body dysmorphic disorder and the ugly truth of Australian healthcare" — documented how poorly BDD is recognised across the Australian clinical workforce, and how often affected patients are cycled through cosmetic clinics without ever being referred to appropriate mental health care.⁵

Pikoos and colleagues have also documented what they call "the Zoom effect": the measurable increase in appearance dissatisfaction and interest in aesthetic treatment that followed the pandemic-era shift to video calling, where patients spent hours each day staring at their own face at close range.⁶ That effect has not gone away. Social media, filters and the normalisation of constant self-surveillance continue to drive presentations that, a decade ago, would have been uncommon.

Why cosmetic procedures typically do not help BDD — and often make it worse

The international literature is consistent and unambiguous on this point. Patients with BDD who undergo cosmetic procedures — surgical or non-surgical — typically report:

No improvement, or worsening, of BDD symptoms post-procedure
Shifting of preoccupation to a new perceived flaw ("symptom migration")
High rates of dissatisfaction with technically successful outcomes
Pursuit of repeated procedures in search of a psychological resolution the procedure cannot deliver
Increased risk of conflict with practitioners, including threats and legal action

Professor David Castle, now at the University of Tasmania and previously director of the body image program at St Vincent's Hospital Melbourne, has published extensively with Rossell on why this happens. The short version: if the underlying problem is a perceptual and cognitive disorder, changing the object being perceived does not change the perception. Evidence-based treatment for BDD is cognitive behavioural therapy with exposure and response prevention, often combined with selective serotonin reuptake inhibitors (SSRIs) at higher doses than typically used for depression.³ ⁵ A filler appointment is not a substitute for either.

None of this means that every cosmetic patient has BDD, or that wanting to change one's appearance is pathological. It means that a subset of patients — a non-trivial subset in this particular setting — will be actively harmed by a procedure that would benefit someone else. The clinician's job is to tell the difference.

What the 2025 AHPRA guidelines actually require

For patients: you should expect a consultation that looks and feels different from what the industry trained you to expect. For practitioners: these are not suggestions.

Before any non-surgical cosmetic procedure, a registered health practitioner is expected to:

Conduct a thorough, evidence-based assessment of the patient's history, motivations, expectations, and psychological, social and cultural context
Specifically assess for psychological conditions — including BDD — that may make a patient unsuitable for the procedure
Refuse treatment and refer the patient to an appropriate independent mental health professional (such as a psychologist) where psychological concerns are identified
Obtain informed consent using both verbal and written information, in plain language, covering the nature, risks, benefits, alternatives and costs of the procedure, and the qualifications of the practitioner performing it
For patients under 18, observe a mandatory seven-day cooling-off period between consent and procedure
Conduct a real-time consultation (video or in person) before any prescription-only cosmetic medicine is prescribed — asynchronous "tick-box" scripting is no longer acceptable
Limit patient assessment for nursing-led services to registered nurses or nurse practitioners specifically; unregulated "cosmetic nurses" without appropriate registration cannot perform this assessment¹

For nurses, the guideline is particularly significant: only registered nurses (RNs) or nurse practitioners (NPs) may undertake patient assessment, closing a loophole that previously allowed junior or unregistered staff to triage patients through a clinic.

Alongside this, the AHPRA Guidelines for advertising a regulated health service (December 2020) continue to apply.⁷ Those guidelines prohibit testimonials, patient stories, unrealistic claims about outcomes, language that creates urgency ("act now," "don't miss out"), gifts and inducements without clear terms and conditions, and the use of terms like "safe" or "risk-free" without acknowledging potential adverse reactions. A clinic that advertises in breach of those rules is a clinic that is also very likely to be cutting corners somewhere else.

The screening tool worth knowing about: the Cosmetic Readiness Questionnaire (CRQ)

The most important practical development in Australian cosmetic medicine in the last five years has been the validation of a psychometric screening tool specifically for this setting.

The Cosmetic Readiness Questionnaire (CRQ), developed by Dr Toni Pikoos, Dr Ben Buchanan, Dr David Hegarty and Professor Susan Rossell, was piloted and then formally validated and published in the Aesthetic Surgery Journal in February 2025.⁸ ⁹ It assesses BDD symptoms alongside other predictors of poor outcomes — psychological distress, self-criticism, perfectionism, unrealistic expectations and motivations — and categorises patients into risk zones. It draws on previously validated instruments including the Body Dysmorphic Disorder Questionnaire – Aesthetic Surgery (BDDQ-AS) and the Appearance Anxiety Inventory.

A shorter 20-item version (CRQ-Brief) exists for clinics that need a rapid triage tool. Both versions generate documentation that supports clinical decision-making and provides a defensible record of the psychological assessment AHPRA now requires.

The tool is not a diagnosis. A red-zone score does not mean a patient has BDD; it means a patient warrants further assessment by an appropriately qualified mental health professional before any procedure proceeds. That is exactly the kind of referral the new guidelines are designed to trigger.

Where to turn: Australian leaders and resources in the BDD field

One of the clearest signs of an ethical cosmetic practice is a willingness to refer patients outward rather than retain them at all costs. The following Australian individuals and organisations have built genuine expertise in this area and should be on the referral list of any serious cosmetic clinic.

Professor Susan Rossell — Director of Clinical Trials and founding Director of the Centre for Mental Health at Swinburne University of Technology, and Adjunct Research Professor in Psychiatry at St Vincent's Hospital Melbourne. Supported by a Senior NHMRC Fellowship. Professor Rossell leads the largest BDD research program in Australia and has published more than 250 peer-reviewed papers across BDD and related disorders.
Dr Toni Pikoos — Clinical psychologist, Postdoctoral Research Fellow at Swinburne's Centre for Mental Health, and co-founder of ReadyMind, the Australian digital platform that delivers the CRQ and independent psychological assessments for cosmetic patients. Dr Pikoos was involved in AHPRA's consultation process in developing the new cosmetic guidelines.
Dr Ben Buchanan — Clinical psychologist and Adjunct Research Fellow at Monash University, specialising in body image and anxiety disorders including BDD. Co-author of the CRQ and co-founder of ReadyMind.
Professor David Castle — Professor of Psychiatry at the University of Tasmania and Co-Director of the Centre for Mental Health Service Innovation in Tasmania. Previously led the body image clinical program at St Vincent's Hospital Melbourne, which developed much of the Australian evidence base on BDD treatment.
The Butterfly Foundation — Australia's national charity for body image issues and eating disorders. Their free, confidential National Helpline (1800 ED HOPE / 1800 33 4673, open 8am–midnight AEST/AEDT, seven days) takes calls about BDD and body image as well as eating disorders. Counsellors are qualified mental health professionals with specialist training in this area.
Centre for Clinical Interventions (CCI), Western Australia — Publishes the Building Body Acceptance workbook, a free evidence-based self-help resource developed specifically for people with BDD symptoms.
ReadyMind — Australian telehealth platform offering independent psychological assessments specifically designed for cosmetic patients, built around the CRQ and its brief version.

Patients in acute distress should call Lifeline on 13 11 14 at any time. For emergencies, 000.

What this means for patients

If you are considering cosmetic injectables in Australia in 2026, the following questions are reasonable to ask your practitioner before your first appointment:

Are you a registered medical practitioner or nurse practitioner? Under what registration number? (Verifiable on the public AHPRA register.)
What psychological screening do you use, and is it a validated tool?
What is your referral process if concerns are identified?
Will I be seen in real time by the prescribing doctor before any prescription is written?
How are risks, realistic outcomes and alternatives documented in your consent process?

A practitioner who treats any of those questions as difficult or unwelcome is a practitioner providing a useful data point.

A well-run consultation should not feel like a sales process. Wanting to decline a patient, or delay, or refer, is a feature of ethical cosmetic practice — not a failure of it.

What this means for practitioners

The 2025 AHPRA guidelines are not going to be relaxed. They are much more likely to be tightened further, particularly around online advertising, influencer partnerships, and prescribing pathways. Practitioners who continue to treat psychological screening as a box-ticking exercise — or who rely on unregistered staff to conduct "consultations" they are not qualified to conduct — face meaningful regulatory exposure under the National Law, including financial penalties under section 133 and potential disciplinary action under the broader professional codes.

The practical response is not complex:

Adopt a validated screening tool. The CRQ and CRQ-Brief are purpose-built and published in a peer-reviewed surgical journal. There is no defensible reason to use anything less rigorous.
Build a real referral network. Have named psychologists and psychiatrists you can refer to, not a Google search.
Document your consent process properly. Verbal plus written, in plain language, covering risks, alternatives and costs.
Separate the prescriber from the injector properly. Real-time consultation, every time, every new script.
Audit your advertising against the December 2020 guidelines. If your marketing relies on testimonials, before-and-after images without appropriate caveats, or urgency language, fix it before AHPRA does.

The practitioners who will do well over the next five years are the ones who treat the new regulatory environment as the floor rather than the ceiling. The minority of patients with undiagnosed BDD who present to cosmetic clinics are among the most vulnerable people our sector sees. Getting this right is not compliance work. It is medicine.

References

Australian Health Practitioner Regulation Agency (Ahpra) and National Boards. Guidelines for Registered Health Practitioners Who Perform Non-Surgical Cosmetic Procedures. Effective 2 September 2025.
Medical Board of Australia. Guidelines for registered medical practitioners who perform cosmetic medical and surgical procedures. Effective 1 July 2023.
Rossell SL. Understanding and treating body dysmorphic disorder. Psychiatry Research. 2023;319:114980. doi:10.1016/j.psychres.2022.114980
Pikoos TD, Rossell SL, Tzimas N, Buzwell S. Is the needle as risky as the knife? The prevalence and risks of body dysmorphic disorder in women undertaking minor cosmetic procedures. Australian & New Zealand Journal of Psychiatry. 2021;55(12):1191-1201. doi:10.1177/0004867421998753
Rossell SL, Castle DJ, Pikoos T, Malcolm A. Body dysmorphic disorder and the ugly truth of Australian healthcare. Australian & New Zealand Journal of Psychiatry. 2023. doi:10.1177/00048674231169441
Pikoos TD, Buzwell S, Sharp G, Rossell SL. The Zoom effect: exploring the impact of video calling on appearance dissatisfaction and interest in aesthetic treatment during the COVID-19 pandemic. Aesthetic Surgery Journal. 2021;41(12):NP2066-NP2075. doi:10.1093/asj/sjab257
Australian Health Practitioner Regulation Agency. Guidelines for advertising a regulated health service. December 2020.
Pikoos TD, Buchanan B, Hegarty D, Rossell SL. The Cosmetic Readiness Questionnaire (CRQ): Validation of a Preoperative Psychological Screening Tool for Aesthetic Procedures. Aesthetic Surgery Journal. 2025;45(2):208-214. doi:10.1093/asj/sjae207
Pikoos TD, Buchanan B, Hegarty D, Rossell SL. Development of a Preoperative Psychological Screening Tool: Piloting the Cosmetic Readiness Questionnaire (Pilot-CRQ). Aesthetic Surgery Journal. 2025;45(2):202-207. doi:10.1093/asj/sjae187

This article is provided for general public health information and education. It is not medical advice and does not replace consultation with a qualified health practitioner. Cosmetic medical procedures carry risks, and outcomes vary between individuals. If you are concerned about body image, BDD or any mental health issue, please contact the Butterfly Foundation on 1800 33 4673, speak to your GP, or in an emergency call 000.

By Dr Robert Laidlaw, Cosmetic Physician with over 15 years' experience. Find me at Concept Cosmetic Medicine Sydney and Bowral.

Body Dysmorphic Disorder and Cosmetic Injectables: What the Evidence — and Australia's Leading Experts — Actually Say